AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...

Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus erythematosus.

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

A phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma. This is an ASCO ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.

AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...